about
Virus maturation as a new HIV-1 therapeutic targetSmall molecule inhibitors of the HIV-1 virulence factor, NefEffect of the Active Site D25N Mutation on the Structure, Stability, and Ligand Binding of the Mature HIV-1 ProteaseEffector kinase coupling enables high-throughput screens for direct HIV-1 Nef antagonists with antiretroviral activity.Chemical library screens targeting an HIV-1 accessory factor/host cell kinase complex identify novel antiretroviral compoundsDeterminants of Mortality among Adult HIV-Infected Patients on Antiretroviral Therapy in a Rural Hospital in Southeastern Nigeria: A 5-Year Cohort Study.Discovery of a diaminoquinoxaline benzenesulfonamide antagonist of HIV-1 Nef function using a yeast-based phenotypic screenCross-clade inhibition of recombinant human immunodeficiency virus type 1 (HIV-1), HIV-2, and simian immunodeficiency virus SIVcpz reverse transcriptases by RNA pseudoknot aptamers.Synthesis and evaluation of orally active small molecule HIV-1 Nef antagonists.Inhibition of HIV-1 replication by P-TEFb inhibitors DRB, seliciclib and flavopiridol correlates with release of free P-TEFb from the large, inactive form of the complexMonoclonal antibodies for prophylaxis and therapy of infectious diseases.Cellulose-bound peptide arrays: preparation and applications.Characterization of antiviral activity of benzamide derivative AH0109 against HIV-1 infection.Impact of human immunodeficiency virus type 1 resistance to protease inhibitors on evolution of resistance to the maturation inhibitor bevirimat (PA-457)Simple, Rapid and Validated LC Determination of Lopinavir in Rat Plasma and its Application in Pharmacokinetic StudiesEffect of Biomolecular Conformation on Docking Simulation: A Case Study on a Potent HIV-1 Protease Inhibitor.Design and characterization of an HIV-specific ribonuclease zymogen.The Role of RNA Polymerase II Elongation Control in HIV-1 Gene Expression, Replication, and Latency.A hybrid design to optimize preparation of lopinavir loaded solid lipid nanoparticles and comparative pharmacokinetic evaluation with marketed lopinavir/ritonavir coformulation.Ritonavir 100 mg does not cause QTc prolongation in healthy subjects: a possible role as CYP3A inhibitor in thorough QTc studies.Valproic acid extends Caenorhabditis elegans lifespan.Effect of grapefruit juice and ritonavir on pharmacokinetics of lopinavir in Wistar rats.
P2860
Q24642446-5C4214CA-3F04-45A9-8602-34A2FB56E3CFQ27013915-869FCA42-E335-408F-9E1C-2F144B40C308Q27649876-4153E862-3D79-489A-9079-BC3C808D9994Q30415176-146B4D32-D313-4366-8AE5-F2419F85C1D8Q33508889-F5AA050E-F97D-40D6-87DE-1314B6F540E5Q34073327-A68033CB-3DBB-411E-BB15-B5F5D292B955Q35042795-E93B2186-AD91-4613-B9A1-E957002CDBEFQ35857522-19D684C9-DE41-46F9-91E5-D6C0E587E634Q35916730-747CEFB0-0F2B-4D1C-922B-973D4BB86297Q35940053-5A29B41C-0FE4-4D1D-9E6D-B2BDDDA1923DQ36989900-09B85473-5042-4FE6-9AF8-2B3AEB0F8F5EQ37024675-BAEDD150-C8AC-497B-BFFA-4A2EF00AA8E3Q37036503-A1D27266-6FE9-4CD1-B876-CBF3CB82DCF9Q37192174-0B591266-583F-4819-B685-D6CF9615FA2EQ39281577-F3B38D5B-2A70-41F8-8518-3A0862DC28A4Q41020492-E1EA30F2-2EB4-4F83-8F2C-1F6D3C02F891Q41204627-EDC3020E-2ABE-4294-AF3D-E8AF6ED55AE6Q42117931-E05515C3-5219-49D1-BBEC-3D30736C7BCBQ42227130-D6CAEB75-D6AD-40B7-A21C-AFC454D879F6Q46090429-B29F57E0-70F3-443C-98ED-1635F888B84CQ46772888-FB40F735-88EC-490D-9485-D1383183D881Q53669986-4CFF9D80-3613-4B3B-B7DC-8118725003BC
P2860
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Current status of antiretroviral therapy.
@ast
Current status of antiretroviral therapy.
@en
type
label
Current status of antiretroviral therapy.
@ast
Current status of antiretroviral therapy.
@en
prefLabel
Current status of antiretroviral therapy.
@ast
Current status of antiretroviral therapy.
@en
P2093
P2860
P1476
Current status of antiretroviral therapy.
@en
P2093
David Warnke
Mary J Kasten
Zelalem Temesgen
P2860
P304
P356
10.1517/14656566.7.12.1541
P407
P577
2006-08-01T00:00:00Z